筛选 Kabasura Kudineer 对 COVID 19 和人体免疫蛋白的有效性:硅学

Architha Vijayalakshmi, Hemalatha S
{"title":"筛选 Kabasura Kudineer 对 COVID 19 和人体免疫蛋白的有效性:硅学","authors":"Architha Vijayalakshmi, Hemalatha S","doi":"10.2174/0126667975281429231206073959","DOIUrl":null,"url":null,"abstract":"\n\nThe advent of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) triggered a pandemic known as coronavirus disease 2019 (COVID-19) in the twenty-first\ncentury. Recent research has revealed several details about SARS-CoV-2 pathogenesis, which has\ngreatly boosted research on COVID-19 vaccines and therapy methods for all the COVID variants.\nHowever, significant doubts about its treatment persist due to its fast mutating capability and its resistance to various drugs administered. Thus, there is a need for a cure to treat all the variants and\ntheir side effects.\n\n\n\nThe main aim of this study is to check 1) the effectiveness of Kabasura Kudineer against\nCOVID 19 2) the side effects of Kabasura Kudineer with the help of immune proteins in humans\n\n\n\nThe molecular docking was carried out between SARS-CoV-2 proteins and immune proteins in humans against Kabasura Kudineer compounds. The ADMET was also carried out to check\nthe Pharmacokinetics.\n\n\n\nThe results showed that chebulagic acid from Terminalia chebula has good binding capability with all the chosen targets1. The drug likeliness screening also proved it a good drug candidate.\n\n\n\nSiddha way of treatment has popped out which has been traditionally used for the\ntreatment of viral respiratory infections. The formulation called Kabasura Kudineer has been proven\nto have antiviral agents and compounds that boost the immune system\n","PeriodicalId":10815,"journal":{"name":"Coronaviruses","volume":"16 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Screening the Effectiveness of Kabasura Kudineer against COVID 19 and\\nImmune Proteins in Humans: In silico\",\"authors\":\"Architha Vijayalakshmi, Hemalatha S\",\"doi\":\"10.2174/0126667975281429231206073959\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n\\nThe advent of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) triggered a pandemic known as coronavirus disease 2019 (COVID-19) in the twenty-first\\ncentury. Recent research has revealed several details about SARS-CoV-2 pathogenesis, which has\\ngreatly boosted research on COVID-19 vaccines and therapy methods for all the COVID variants.\\nHowever, significant doubts about its treatment persist due to its fast mutating capability and its resistance to various drugs administered. Thus, there is a need for a cure to treat all the variants and\\ntheir side effects.\\n\\n\\n\\nThe main aim of this study is to check 1) the effectiveness of Kabasura Kudineer against\\nCOVID 19 2) the side effects of Kabasura Kudineer with the help of immune proteins in humans\\n\\n\\n\\nThe molecular docking was carried out between SARS-CoV-2 proteins and immune proteins in humans against Kabasura Kudineer compounds. The ADMET was also carried out to check\\nthe Pharmacokinetics.\\n\\n\\n\\nThe results showed that chebulagic acid from Terminalia chebula has good binding capability with all the chosen targets1. The drug likeliness screening also proved it a good drug candidate.\\n\\n\\n\\nSiddha way of treatment has popped out which has been traditionally used for the\\ntreatment of viral respiratory infections. The formulation called Kabasura Kudineer has been proven\\nto have antiviral agents and compounds that boost the immune system\\n\",\"PeriodicalId\":10815,\"journal\":{\"name\":\"Coronaviruses\",\"volume\":\"16 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-12-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Coronaviruses\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/0126667975281429231206073959\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Coronaviruses","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0126667975281429231206073959","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

严重急性呼吸系统综合征冠状病毒 2(SARSCoV-2)的出现引发了 21 世纪冠状病毒病 2019(COVID-19)的大流行。最近的研究揭示了 SARS-CoV-2 发病机制的一些细节,极大地推动了 COVID-19 疫苗和所有 COVID 变种治疗方法的研究。本研究的主要目的是检测 1) Kabasura Kudineer 对 COVID 19 的有效性 2) Kabasura Kudineer 在人体免疫蛋白的帮助下产生的副作用。结果表明,来自诃子树的诃子酸与所有选定的靶标都有很好的结合能力1。结果表明,从诃子中提取的诃子酸与所有选定的靶点都有很好的结合能力1,药物相似性筛选也证明它是一种很好的候选药物。被称为 Kabasura Kudineer 的配方已被证明具有抗病毒剂和增强免疫系统的化合物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Screening the Effectiveness of Kabasura Kudineer against COVID 19 and Immune Proteins in Humans: In silico
The advent of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) triggered a pandemic known as coronavirus disease 2019 (COVID-19) in the twenty-first century. Recent research has revealed several details about SARS-CoV-2 pathogenesis, which has greatly boosted research on COVID-19 vaccines and therapy methods for all the COVID variants. However, significant doubts about its treatment persist due to its fast mutating capability and its resistance to various drugs administered. Thus, there is a need for a cure to treat all the variants and their side effects. The main aim of this study is to check 1) the effectiveness of Kabasura Kudineer against COVID 19 2) the side effects of Kabasura Kudineer with the help of immune proteins in humans The molecular docking was carried out between SARS-CoV-2 proteins and immune proteins in humans against Kabasura Kudineer compounds. The ADMET was also carried out to check the Pharmacokinetics. The results showed that chebulagic acid from Terminalia chebula has good binding capability with all the chosen targets1. The drug likeliness screening also proved it a good drug candidate. Siddha way of treatment has popped out which has been traditionally used for the treatment of viral respiratory infections. The formulation called Kabasura Kudineer has been proven to have antiviral agents and compounds that boost the immune system
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.50
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信